OMER News and Press, Omeros Corporation From 05/10/21

Omeros Corp (OMER) Q1 2021 Earnings Conference Call May 10, 2021, 16:30 ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Co-Founder, Chairman, CEO & President Nadia Dac - Chief Commercial Officer Michael Jacobsen - CAO, VP, Finance & Treasurer Steven ...

Omeros (OMER): Q1 GAAP EPS of -$0.57 misses by $0.06.Revenue of $21.06M (-10.4% Y/Y) beats by $0.36M.Press Release For further details see: Omeros EPS misses by $0.06, beats on revenue

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicat...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Easte...

Omeros (OMER) announces that the Centers for Disease Control and Prevention ((CDC)) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA).The absence of a speci...

Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HS...

FDA action approving narsoplimab in treatment of HSCT-TMA in Omeros' upcoming PDUFA date has the potential to vault Omeros into multibagger territory overnight. Omeros' narsoplimab in treatment of severely ill COVID-19 patients presents an interesting opportunity. Omeros' long str...

Today, we revisit Akari Therapeutics, a small developmental firm based in London, for the first time since last spring. Despite the impacts of the pandemic, the company has managed to kick off a couple of late-stage trials since we last looked at it. A full investment analysis fol...

-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients -- Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COV...

Maintaining their buy rating, the analysts at Bank of America have upgraded the price target of Omeros Corporation ([[OMER]] +1.2%) citing expert views on the potential of the company’s experimental monoclonal antibody narsoplimab for transplant-associated thrombotic microangiopathy.No...